CorePlus Integrates AI-Powered Prostate Cancer Risk Stratification Tool Into its Diagnostic Pathway

CorePlus has integrated the ArteraAI Prostate Test into its diagnostic workflows, thereby becoming the first laboratory in Puerto Rico to bring this guideline-recommended artificial intelligence (AI) test into routine clinical use.

The ArteraAI Prostate Test is an advanced risk stratification tool to help personalize and optimize treatments for patients battling localized prostate cancer.

The collaboration merges CorePlus’s expertise in precision anatomic and clinical pathology with Artera’s validated multimodal artificial intelligence (MMAI) platform. Together, the organizations seek to improve diagnostic accuracy, accelerate clinical decision-making, and deliver more personalized care for prostate cancer patients.

Unlike many other laboratory-developed tests, the ArteraAI Prostate Test is an AI assay that analyzes the digital pathology images of prostate cancer biopsies. It analyzes images of pre-existing histopathology slides, so the test consumes no tissue. Upon completing a successful validation process, CorePlus can seamlessly send biopsy slide images to Artera and typically receive results within 24 hours. Since the collaboration began in 2023, CorePlus has delivered the test to its large urologist referral network across Puerto Rico.

Prostate cancer is the second-leading cause of cancer death in American men, behind only lung cancer. Although prostate cancer is a serious disease, most patients do not die from it; in fact, more than 3.5 million U.S. men who have been diagnosed with prostate cancer are still alive. The variability in prostate cancer aggressiveness can make it difficult for clinicians and patients to determine the right treatment options, as both under- and over-treatment can be problematic.

The ArteraAI Prostate Test is the only assay included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) that can both predict therapy benefit and forecast long-term outcomes in localized prostate cancer. The ArteraAI Prostate Test can increase patients’ confidence by offering more clarity around whether they will benefit from a specific treatment course, according to CorePlus management.

“We are proud of our close partnership with Artera, expanding from initial research and development efforts into clinical usage and now operational integration. Through persistence and precision, our teams have delivered AI-enabled insights to our largely underserved patient population, faster and more conveniently than even most leading academic centers,” CorePlus Founder/CEO Mariano de Socarraz said. “CorePlus continues its mission of transforming patient care through precision pathology, turning years of research into real-life impact for patients.”

The collaboration also extends into the scientific community. CorePlus Chief Medical Officer Juan C. Santa Rosario, M.D., is slated to deliver an oral presentation of the teams’ joint research, “Validation of a multimodal AI biomarker in a Puerto Rican cohort with localized prostate cancer,” at the Digital Pathology Association’s PathVisions conference on Oct. 17.

“At Artera, our mission in making precision oncology accessible means proving it works across every community, and Dr. Santa Rosario’s research reinforces this,” Artera Co-Founder/CEO Andre Esteva stated. “By combining digital pathology with multimodal data analysis, we provide clinicians with the tools they need to deliver truly personalized care.”

By uniting AI-powered diagnostics with precision pathology, CorePlus and Artera are working to ensure that prostate cancer patients in Puerto Rico receive earlier, more accurate diagnoses and timely access to the treatments most likely to benefit them.

CorePlus is a fully digital precision pathology and clinical laboratory serving physicians and patients in Puerto Rico from its facilities in Carolina and Ponce. Founded in 1996, CorePlus reached 100% whole-slide imaging for primary diagnosis in January 2020 and has since performed more than 250,000 AI-assisted analyses and over 1 million prostate core reviews. CorePlus adopts innovative technologies, including AI-enabled digital pathology, to bring advanced medical solutions to its physician partners and patients.

Artera is a precision medicine provider, leveraging MMAI to personalize cancer care. Artera’s MMAI platform leverages a patient’s digitized histopathology images along with the patient’s clinical data to determine cancer aggressiveness and predict therapy benefit. This approach has been validated in multiple Phase 3 randomized trials across different cancers and is available in multiple versions across the globe. Artera’s U.S. Food and Drug Administration-authorized software products include ArteraAI Prostate (de novo authorization) and ArteraAI Breast (510(k) clearance). In addition, Artera has received CE Marking for its prostate and breast cancer in-vitro diagnostic tests, supporting regulated availability in international markets.

Artera’s flagship product, the ArteraAI Prostate Test, is commercially available as a laboratory-developed test in the United States and internationally through its distribution partners. The ArteraAI Prostate Test is reportedly the first of its kind to deliver both prognostic and predictive insights for patients with prostate cancer, empowering clinicians and patients to make more informed treatment decisions. Artera is based in Los Altos, Calif., and its CLIA-certified clinical laboratory is located in Jacksonville, Fla.